Eli Lilly will present new data from across its oncology portfolio at the European Society for Medical Oncology Congress, held from 23 to 27 October in Madrid, Spain. The highlights include the first Phase 1 data for sofetabart mipitecan (Sofe-M), Lilly’s investigational antibody-drug conjugate targeting folate receptor alpha (FRα), combined with bevacizumab in platinum sensitive ovarian cancer. The company will also share updated findings for olomorasib, Retevmo (selpercatinib) and Verzenio (abemaciclib) in lung, thyroid and breast cancers.
The Sofe-M data will be given in a rapid oral presentation and support the ongoing Phase 3 trial of the drug in platinum sensitive ovarian cancer. Updated first line data for olomorasib, an investigational KRAS G12C inhibitor, will also be shown in a rapid oral presentation. It combines an integrated analysis from the Phase 1/2 LOXO-RAS-20001 trial with the safety lead in portion of the Phase 3 SUNRAY-01 trial. The analysis assessed olomorasib alongside chemoimmunotherapy (pembrolizumab, pemetrexed and platinum) as a possible first line treatment for advanced or metastatic KRAS G12C mutant non small cell lung cancer (NSCLC), and supports the ongoing Phase 3 trial in that setting.
Updated results from the Phase 3 LIBRETTO-531 study will be presented as a proffered paper. The study compares Retevmo (selpercatinib), a RET kinase inhibitor, with cabozantinib or vandetanib in advanced, kinase inhibitor naïve, RET mutant medullary thyroid cancer. These data have already supported global approvals of Retevmo in this setting.
Overall survival data from the Phase 3 postMONARCH trial will be given in a rapid oral presentation. The trial tested Verzenio (abemaciclib), a CDK4/6 inhibitor, plus fulvestrant in HR positive, HER2 negative advanced breast cancer after progression on a prior CDK4/6 inhibitor and endocrine therapy. Lilly says the results support the abemaciclib plus imlunestrant findings from EMBER-3 and add to the evidence for switching both the endocrine therapy and the CDK4/6 inhibitor at progression in metastatic breast cancer.
Jacob Van Naarden, executive vice president and president of Lilly Oncology, said the presentations reflect both the breadth of the portfolio and its focus on following compelling science wherever it could change care. He said the company is especially encouraged by the Sofe-M data in platinum sensitive ovarian cancer, which build on earlier results in platinum resistant disease and are a critical step as the Phase 3 FRAmework-01 study advances across both settings. He described the updated first line olomorasib data as very promising, with clinical activity and a safety profile in line with earlier findings, reinforcing the case for targeted therapy from the start of treatment. Together with the thyroid and breast cancer data, he said, the presentations show meaningful momentum towards better care for people with cancer.
Lilly presentations at ESMO 2026
Sofetabart mipitecan (Sofe-M), investigational ADC targeting FRα
| Abstract title | Lead author | Presentation details (CET) |
|---|---|---|
| Model-informed Phase 3 dose selection for antibody-drug conjugate (ADC) sofetabart mipitecan (Sofe-M): First prospective application of a clinical utility index (CUI) | Jean-Sebastien Frenel | Poster #1016P, poster display session, Friday 23 October, 15:15 to 16:00 |
| Efficacy and safety of sofetabart mipitecan (Sofe-M), a folate receptor alpha (FRα) targeting antibody drug conjugate (ADC), plus bevacizumab in recurrent platinum sensitive ovarian cancer (PSOC) | Chrisann Kyi | Rapid oral #1246RO, Rapid oral 2: Gynecological cancers, Saturday 24 October, 8:30 to 10:00 |
| Sofetabart mipitecan (Sofe-M) in patients ≥65 y with platinum-resistant and -sensitive ovarian cancer (PROC/PSOC) from the first-in-human phase 1 study | Ana Oaknin | Poster #1288P, poster display session, Monday 26 October, 12:00 to 12:45 |
Olomorasib, investigational KRAS G12C inhibitor
| Abstract title | Lead author | Presentation details (CET) |
|---|---|---|
| First-line (1L) olomorasib + chemoimmunotherapy (Chemo-IO) in KRAS G12C-mutant NSCLC: Updated results from the LOXO-RAS-20001 and SUNRAY-01 trials | Marcelo V. Negrao | Rapid oral #2652RO, Rapid oral 2: NSCLC, metastatic, Sunday 25 October, 8:30 to 10:00 |
| First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01 | Melissa L. Johnson | Poster #2683P, poster display session, Monday 26 October, 12:00 to 12:45 |
Retevmo (selpercatinib), RET kinase inhibitor
| Abstract title | Lead author | Presentation details (CET) |
|---|---|---|
| Updated results of randomized Phase 3 study of selpercatinib vs cabozantinib or vandetanib (C/V) in advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer (MTC) | Jaume Capdevila | Proffered paper #4208O, Proffered paper: NETs and endocrine tumors, Monday 26 October, 10:15 to 11:45 |
Verzenio (abemaciclib), CDK4/6 inhibitor
| Abstract title | Lead author | Presentation details (CET) |
|---|---|---|
| Association of p27 V109G SNP zygosity with outcomes and abemaciclib treatment effect in HR+, HER2– high-risk early breast cancer: results from monarchE | Miguel Quintela-Fandino | Poster #4498P, poster display session, Friday 23 October, 15:15 to 16:00 |
| Overall survival from the Phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2– advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy | Kevin Kalinsky | Rapid oral #1RO, Rapid oral 1: Breast cancer, advanced stage, Saturday 24 October, 10:15 to 11:45 |
| Three-month persistence and adherence to adjuvant abemaciclib in high-risk HR+, HER2– early breast cancer: real world data from ABSIDE-S | Isabel Blancas López-Barajas | ePoster #1933eP, ePoster session, Friday 23 October, 8:00 |
| Treatment persistence and clinical characteristics in patients with HR+, HER2–, high-risk early breast cancer (EBC) treated with abemaciclib: A multi-country real-world study | Hitomi Sakai | ePoster #615eP, ePoster session, Friday 23 October, 8:00 |
